PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

Coffey, G., Rani, A., Betz, A., Pak, Y., Haberstock-Debic, H., Pandey, A., Hollenbach, S., Gretler, D.D., Mant, T., Jurcevic, S. and Simha, U. 2017. PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. Journal of Clinical Pharmacology. 57 (2), pp. 194-210. https://doi.org/10.1002/jcph.794

TitlePRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
AuthorsCoffey, G.
Rani, A.
Betz, A.
Pak, Y.
Haberstock-Debic, H.
Pandey, A.
Hollenbach, S.
Gretler, D.D.
Mant, T.
Jurcevic, S.
Simha, U.
Abstract

The spleen tyrosine kinase (SYK) regulates immune cell activation in response to engagement of a variety of receptors, making it an intriguing target for the treatment of inflammatory and autoimmune disorders as well as certain B-cell malignancies. We have previously reported on the discovery and preclinical characterization of PRT062607, a potent and highly selective inhibitor of SYK that exhibits robust anti-inflammatory activity in a variety of animal models. Here we present data from our first human studies aimed at characterizing the pharmacokinetics (PK), pharmacodynamics (PD), and safety of PRT062607 in healthy volunteers following single and multiple oral administrations. PRT062607 demonstrated a favorable PK profile and the ability to completely inhibit SYK activity in multiple whole-blood assays. The PD half-life in the more sensitive assays was approximately 24 hours and returned to predose levels by 72 hours. Selectivity for SYK was observed at all dose levels tested. Analysis of the PK/PD relationship indicated an IC50 of 324 nM for inhibition of B-cell antigen receptor-mediated B-cell activation and 205 nM for inhibition of FcεRI-mediated basophil degranulation. PRT062607 was safe and well tolerated across the entire range of doses. Clinical PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of autoimmune disease. PRT062607 has a desirable PK profile and is capable of safely, potently, and selectively suppressing SYK kinase function in humans following once-daily oral dosing.

JournalJournal of Clinical Pharmacology
Journal citation57 (2), pp. 194-210
ISSN0091-2700
Year2017
PublisherWiley
Publisher's version
Digital Object Identifier (DOI)https://doi.org/10.1002/jcph.794
Publication dates
Published17 Aug 2017
Published in printFeb 2017
FunderBritish Heart Foundation (BHF)
LicenseCC BY-NC-ND 4.0
Supplementary data or files
File
Supplementary data or files
File
Supplementary data or files
File
Supplementary data or files
File

Related outputs

The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis)
Rashvand, S., Dishkelov, A. and Jurcevic, S. 2024. The role of Inflammation in platelet activation (and in anti-neutrophil cytoplasmic antibody (ANCA) vasculitis). GTH Congress 2024 – 68th Annual Meeting of the Society of Thrombosis and Haemostasis Research – Building Bridges in Coagulation. Vienna, Austria 27 Feb - 01 Mar 2024 Georg Thieme Verlag. https://doi.org/10.1055/s-0044-1779178

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells
Mortoglou, M., Miralles, F., Arisan, E.D., Dart, A., Jurcevic, S., Lange, S. and Uysal Onganer, P. 2022. microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells. International Journal of Molecular Sciences. 23 (3) 1275. https://doi.org/10.3390/ijms23031275

Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1)
Lee, M.H., Thomas, J.L., Liao, C.L., Jurcevic, S., Crnogorac-Jurcevic, T. and Lin, H.Y. 2018. Epitope recognition of peptide-imprinted polymers for Regenerating protein 1 (REG1). Separation and Purification Technology. 192, pp. 213-219. https://doi.org/10.1016/j.seppur.2017.09.071

Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma
Jurcevic, S., Lee, M-H., Thomas, J.L., Liao, C-L., Crnogorac-Jurcevic, T. and Lin, H-Y. 2017. Polymers imprinted with three REG1B peptides for electrochemical determination of Regenerating Protein 1B, a urinary biomarker for pancreatic ductal adenocarcinoma. Microchimica Acta. 184 (6), p. 1773–1780. https://doi.org/10.1007/s00604-017-2169-4

Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans
Jurcevic, S., Juif, P.E., Hamid, C., Greenlaw, R., D'Ambrosio, D. and Dingemanse, J. 2016. Effects of multiple-dose ponesimod, a selective SIP1 receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy. 11, pp. 123-131. https://doi.org/10.2147/DDDT.S120399

The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions.
Jurcevic, S., Humfrey, C., Uddin, M., Warrington, S., Larsson, B. and Keen, C. 2015. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. . 80 (6), pp. 1324-36. https://doi.org/10.1111/bcp.12724

The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease.
Jakubowski, J.A., Zhou, C., Winters, K.J., Lachno, D.R., Howard, J., Payne, C.D., Mant, T., Jurcevic, S. and Frelinger, A.L. 2015. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 26 (5), pp. 474-479. https://doi.org/10.3109/09537104.2014.940887

FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells
Rani, A., Greenlaw, R., Runglall, M., Jurcevic, S. and John, S. 2014. FRA2 is a STAT5 target gene regulated by IL-2 in human CD4 T cells. PLoS ONE. 9 (2), p. e90370. https://doi.org/10.1371/journal.pone.0090370

A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation
Jakubowski, J.A., Zhou, C., Jurcevic, S., Winters, K.J., Lachno, D.R., Frelinger, A.L., Gupta, N., Howard, J., Payne, C.D. and Mant, T. 2014. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thrombosis Research. 133 (2), pp. 190-5. https://doi.org/10.1016/j.thromres.2013.12.008

Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice
Alkhamis, T., Barbic, J., Crnogorac-Jurcevic, T., Greenlaw, R.E., Peakman, M. and Jurcevic, S. 2012. Antibody combination therapy targeting CD25, CD70 and CD8 reduces islet inflammation and improves glycaemia in diabetic mice. Clinical & Experimental Immunology. 170 (2), p. 139–148 PMC3482360. https://doi.org/10.1111/j.1365-2249.2012.04651.x

The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival
Jurcevic, S., Shariff, H., Greenlaw, R.E., Meader, L., Gardner, N., Yagita, H., Coccia, M. and Mamode, N. 2011. The Role of the Fc Region in CD70-specific Antibody Effects on Cardiac Transplant Survival. Transplantation. 92 (11), pp. 1194-1201. https://doi.org/10.1097/TP.0b013e3182347ecd

An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients
Jurcevic, S. 2008. An Antibody Combination That Targets Activated T Cells Extends Graft Survival in Sensitized Recipients. American Journal of Transplantation. 8 (11), pp. 2272-2282. https://doi.org/10.1111/j.1600-6143.2008.02393.x

Transplant tolerance: models, concepts and facts
Monk, N.J., Hargreaves, R.E.G., Simpson, E., Dyson, J.P. and Jurcevic, S. 2006. Transplant tolerance: models, concepts and facts. Journal of Molecular Medicine. 84 (4), pp. 295-304. https://doi.org/10.1007/s00109-005-0006-4

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation
Jurcevic, S., Braselmann, S., Taylor, V., Zhao, H., Wang, S. and Masuda, E.S. 2006. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. Journal of Pharmacology and Experimental Therapeutics. 319 (3), pp. 998-1008 109058/3152109. https://doi.org/10.1124/jpet.106.109058

Selective depletion of activated T cells: the CD40L-specific antibody experience
Hargreaves, R.E.G., Monk, N.J. and Jurcevic, S. 2004. Selective depletion of activated T cells: the CD40L-specific antibody experience. TRENDS in Molecular Medicine. 10 (3), pp. 130-135. https://doi.org/10.1016/j.molmed.2004.01.009

Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade
Monk, N.J., Hargreaves, R.E.G., Marsh, J.E., Farrar, C.A., Sacks, S.H., Millrain, M., Simpson, E., Dyson, J. and Jurcevic, S. 2003. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nature Medicine. 9 (10), pp. 1275-1280. https://doi.org/10.1038/nm931

Permalink - https://westminsterresearch.westminster.ac.uk/item/q169w/prt062607-achieves-complete-inhibition-of-the-spleen-tyrosine-kinase-at-tolerated-exposures-following-oral-dosing-in-healthy-volunteers


Share this

Usage statistics

109 total views
418 total downloads
These values cover views and downloads from WestminsterResearch and are for the period from September 2nd 2018, when this repository was created.